Current articles and info about your health

Thursday, 17th May 2012

   home     about     authors     news     books     xml feed     sitemap     privacy     contact us

There are 15 users online

add to favorites
 make home page


Addiction Issues
 Aging
 Allergies & Sinuses
 Alternative Medicine
 Beauty & Health
 Books & Reading
 Common Illnesses
 Community Service
 Diabetic Health
 Dieting
 Diseases
 Environmental Health
 Exercise and Fitness
 Health Education
 Health Industry
 Health Insurance
 Health Legal Issues
 Health Technology
 Healthcare Services
 Healthy Eating
 Medical Equipment & Products
 Men's Health
 Mental and Emotional Health
 Muscle & Back Pain
 Nutrition and Supplements
 Pediatrics
 Pet Health
 Physical Therapy & Massage
 Prevention Health
 Vision Health
 Weight Management
 Women's Health

Our Newsletter

Sign up for our free
Health-Informant.com Ezine
Get all the latest Health news delivered right to your mailbox.

First Name:

Your Email:



We will never rent, share or sell your name to anyone else... ever! We respect your privacy!
  Other Resources


For other sources of health news, tips, and information, visit our resources page

 

  Submit an Article


Would you like to have your article posted? Click Here
 

 
 

Advanced Biological Laboratories SA (ABL, S.A)
Added: 03/30/2005
 Type: Summary
 Viewed: 1181 time(s)
 [ Not Rated Yet ]
How would you rate this article:    Bad Good   Go » 
Advanced Biological Laboratories SA (ABL, S.A)

Topsfield, MA  March 30, 2005 -- ABL, SA (A Luxembourg Company) with TherapyEdge Inc. (Durham, NC) today announced it had signed a license agreement to use the Stanford University HIVdb resistance interpretation algorithm in their ViroScorer Report.

The ViroScorer HIV report is part of the ViroScore Suite which provides decision support to HIV doctors by helping them select the best therapy for an HIV patient based on the past and current resistance to HIV drugs. The report has picked up a lot of support from opinion leaders in HIV clinical research as it offers a global interpretation based on research from six leading research centers across the world.

Jean-Claude Schmit, a leading HIV resistance researcher in Europe and the Clinical Director of the Virology Lab at Centre Hospital de Luxembourg, the author of one of the European algorithms in the report, has praised the ABL team for broadening the product line. "The ViroScore Test and the Suite of tools for individual patient treatment and longitudinal research are now unmatched in the Field. Stanford has some of the best researchers in the world and a large pool of genetic sequence data to create and refine their algorithm."

The Stanford Algorithm will round out the resistance interpretation for ABL customers across the globe and in particular in the US where ABL is expanding. Chairman of the board of ABL, Arsene Kronshagen said that, "this algorithm will help us expand in the Americas because it is widely accepted as the standard for HIV resistance interpretation in the region."

ABL sells the resistance interpretation platform to diagnostic companies, HIV researchers and individual physicians treating HIV. The ViroScore Suite of tools includes an enterprise class database for the storage of genetic sequence data, analysis tools for reporting on the relationships between clinical outcomes and virus mutations, phylogenetic analysis of sequence groups and numerous tools to assist the physicians and researchers in optimizing the use of complex genetic data.

ABL will also use the Stanford algorithm in the "ViroScore-PLUS" Report which provides resistance interpretation based on the patients current and past resistance history. Ronan Boulme, VP of Research and Development added, "Our clinical partners have requested we take into account the historic resistance profile of the patient, even if some mutations were not currently present due to lack of drug pressure. We are proud to announce this functionality when more and more governments and insurance agencies are recognizing the value of genotype testing and reimbursing for its cost."

ABL includes the Stanford Algorithm in version 6.2 of the ViroScore Suite released March 28th and is offering upgrades to existing customers in over 36 countries.

To license the ABL products, to learn about our company or to start a research partnership, please visit www.ablsa.com. ABL is currently seeking a distribution partner for their technologies in the North American region.

Press Contact:
Hank Head
Article Pages:  1  



  Article Comments   Add Comment | View All (0)
    There are currently no comments for this article.


Advanced Search

Good Resources

Create a Happier Life

High Protein, Low Cal Food

Martial Arts Reviews


Affiliate With Us
 


All content © 2012 Webmaster, Advanced Biological Laboratories SA (ABL, S.A) :: Health-Informant.com.